[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100517205":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":56,"collaborators":58,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":21,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":21,"enrollmentInfo":71,"targetDuration":21,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":38,"whyStopped":21,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of California, Davis","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: PET\u002FCT scans","EXPERIMENTAL","Each subject will undergo a dynamic 18F-FDG PET\u002FCT scan and a dynamic 11C-butanol PET\u002FCT scan on the EXPLORER total-body PET\u002FCT system",[13,14],"Drug: 18F-FDG","Drug: 11C-butanol",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","18F-FDG","Each subject will undergo a dynamic 18F-FDG PET\u002FCT scan (this drug is FDA approved) and a dynamic 11C-butanol PET\u002FCT scan (this drug is under an IND) on the EXPLORER total-body PET\u002FCT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.",[9],null,{"type":17,"name":23,"description":19,"armGroupLabels":24,"otherNames":21},"11C-butanol",[9],[26],{"name":27,"affiliation":5,"role":28},"Guobao Wang, PhD","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":21,"email":34},"Clinical Research Team","CONTACT","916-731-9004","research-radiology-som@health.ucdavis.edu",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"UC Davis EXPLORER Molecular Imaging Center","RECRUITING","Sacramento","California","95816","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-121.4944,38.58157,{"lat":48,"lon":47},[51,55],{"name":52,"role":32,"phone":53,"phoneExt":21,"email":54},"Dana Little, MS","916-734-7749","dalittle@ucdavis.edu",{"name":27,"role":28,"phone":21,"phoneExt":21,"email":21},{"type":57,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR",[59],{"name":60,"class":61},"National Institute for Biomedical Imaging and Bioengineering (NIBIB)","NIH","100517205","early-phase-1-single-tracer-multiparametric-pet-imaging-100517205",false,"NCT06014515","Single-tracer Multiparametric PET Imaging","Inclusion Criteria:\n\n1. Inclusion Criteria for all research participants:\n\n   * Adults (age ≥ 18 years old)\n   * Ability to understand and willingness to sign an informed consent form\n   * Ability to adhere to the study visit schedule and other protocol requirements.\n   * Willing and able to fast for at least 6 hours before and for the duration of the scan\n   * No strenuous exercise for 24 hours prior to being scanned\n   * Willing to lie on the scanner bed for up to 60 minutes\n   * Free of active COVID-19 symptoms\n2. Inclusion Criteria for healthy volunteers only:\n\n   • Free of history of cardiovascular, inflammatory, infections or metabolic diseases that would result in changes in normal tissue perfusion and\u002For metabolism.\n3. Inclusion Criteria for patients with disease:\n\n   * Patients with clinically acute or chronic conditions such as cardiovascular, cardiometabolic, or cardiopulmonary diseases, which may include but are not limited to ischemic heart disease, myocarditis, arrhythmias, heart failure, nonalcoholic fatty liver disease, COVID-related sequala, diabetes, hypertension, or renal disease that would result in changes in normal tissue perfusion and\u002For metabolism.\n\nExclusion Criteria:\n\nParticipants are not eligible if they meet ANY of the following criteria:\n\n* Self-reported history of dysphoria or anxiety in closed spaces\n* Body weight \\>240 kg due to limitations of the scanner bed\n* Pregnant or breast-feeding (due to risks of ionizing radiation; urine pregnancy test will be administered prior to start of each PET\u002FCT session for all participants between 18 to 60 years old who are able to get pregnant, unless documented hysterectomy or bilateral ovarian removal is available)\n* Blood glucose greater than 200 as assessed by fingerstick method before injection of 18F-FDG\n* Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.\n* Prisoners\n* Any condition that would prevent the understanding or rendering of informed consent.\n* Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.",true,"ALL","18 Years",{"count":72,"type":73},60,"ESTIMATED","INTERVENTIONAL",[76],"EARLY_PHASE1","The overarching goal of this project is to develop and evaluate a single-tracer multiparametric positron emission tomography (PET) imaging solution for simultaneous imaging of blood flow and glucose metabolism using 18F-fluorodeoxyglucose (FDG) alone. The investigators working hypothesis is that quantitative blood flow can be extracted from dynamic 18F-FDG PET data by use of tracer kinetic modeling, in addition to glucose metabolism that 18F-FDG is conventionally used for.",[79,80],"Healthy Subjects","Cardiovascular Disease",[82],"total body positron emission tomography","2026-03-09",{"date":85,"type":86},"2026-03-10","ACTUAL",{"date":88,"type":86},"2024-02-14",{"date":90,"type":73},"2033-08",{"name":5,"class":6},1]